Table 1.
Cohort Demographics and Morbidities (n = 124)
| n (%) | |
|---|---|
| Male | 91 (73.4) |
| Age, y | |
| 20–64 | 50 (40.3) |
| 65–95 | 74 (59.7) |
| Race | |
| White | 82 (66.1) |
| Black | 22 (17.7) |
| Other | 20 (16.1) |
| Ethnicity | |
| Non-Hispanic | 108 (87.1) |
| Hispanic | 8 (6.5) |
| COVID-positive | |
| No | 110 (88.7) |
| Yes, before first dose | 10/121 (8.3) |
| Yes, at 1-m serum collection | 10/121 (8.3) |
| Yes, at 3-m serum collection | 12/121 (9.9) |
| Yes, at 6-m serum collection | 12/121 (9.9) |
| Yes, at 10-m serum collection | 10/72 (5.8) |
| Yes, at 12-m serum collection | 23/88 (26.1) |
| Chronic heart disease | 77 (62.1) |
| Lung disease | 67 (54.0) |
| Current steroid use | 19 (15.3) |
| Liver disease | 8 (6.5) |
| GFR in mL/min/1.73 m2, mean (SD)a | 69.6 (31.2) |
| >60 | 87 (70.2) |
| 30–60 | 18 (14.5) |
| <30 | 17 (13.7) |
| Malignancy | |
| Solid | 31 (25) |
| Hematological | 5 (4) |
| Both | 2 (1.6) |
| Diabetes mellitus | 39 (31.5) |
| TIA-CVA | 13 (10.5) |
| Dementia | 5 (4.0) |
| HIV-Transplant-Rheum | 18 (14.6) |
| Hemoglobin A1c, median [Q1,Q3]b,c | 5.6 [5.2,6.1] |
| BMI, median [Q1,Q3]b,c | 28.4 [24.8,31.5] |
Abbreviations: BMI, body mass index; COVID, coronavirus disease; GFR, glomerular filtration rate; SD, standard deviation; TIA-CVA, transient ischemic attack-cerebrovascular accident.
a
Multimodal distributions (Hartigan dip test).
b
Non-normal distributions (Shapiro-Wilk test).
c
Far outliers in Tukey test.